Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Lack of technology transfer stands out as a formidable barrier
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
Subscribe To Our Newsletter & Stay Updated